Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events
Open Access
- 7 October 2003
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (10), 2769-2772
- https://doi.org/10.1002/art.11277
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first‐line therapyArthritis Care & Research, 2002
- Criteria for early rheumatoid arthritis: From Bayes' law revisited to new thoughts on pathogenesisArthritis & Rheumatism, 2002
- Treating rheumatoid arthritis early: A window of opportunity?Arthritis & Rheumatism, 2002
- How is it best to treat early rheumatoid arthritis patients?Best Practice & Research Clinical Rheumatology, 2001
- The changing face of rheumatoid arthritis therapy: Results of serial surveysArthritis & Rheumatism, 2000
- Evidence-based medicine or medicines-based evidence?Annals Of The Rheumatic Diseases, 1998
- Methotrexate hepatotoxicity: What is the evidence?Inflammation Research, 1998
- Creating a care‐effective cost‐effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: comment on the article by kremer et alArthritis & Rheumatism, 1995
- Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients treated with methotrexate: comment on the article by kremer et alArthritis & Rheumatism, 1994
- Methotrexate for Rheumatoid ArthritisArthritis & Rheumatism, 1994